SciELO - Scientific Electronic Library Online

 
vol.91 número3Asociación entre el polimorfismo rs9939609 del gen FTO y marcadores de adiposidad en población infantil chilenaTrastornos hereditarios de la coagulación en adolescentes con sangrado menstrual excesivo, ¿debemos evaluar la vía fibrinolítica? índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Revista chilena de pediatría

versión impresa ISSN 0370-4106

Resumen

GARRIDO MAGANA, Eulalia et al. Thyroid dysfunction due to 131I-metaiodobenzylguanidine in patients with neuroblastoma. Rev. chil. pediatr. [online]. 2020, vol.91, n.3, pp.379-384. ISSN 0370-4106.  http://dx.doi.org/10.32641/rchped.v91i3.1237.

Introduction:

The treatment of advanced neuroblastoma includes chemotherapy, surgery, and radiotherapy with 131-I-Metaiodobenzylguanidine (131-I-MIBG). Despite strategies to protect thyroid function, its dysfunction is reported between 12 and 85%.

Objective:

To identify the frequency of thyroid dys function in cases of neuroblastoma treated with 131-I-MIBG.

Patients and Method:

Cross-sectional study. We included all the cases with neuroblastoma treated with 131-I-MIBG between 2002 and 2015, with complete somatometry, and complete thyroid profile (TSH, free and total T3 and T4, and anti-thyroglobulin and antiperoxidase antibodies).

Results:

27 patients were identified out of which eleven died (40%). Out of the 16 surviving cases, 9 (56%) presented thyroid dysfunction: 2 (13%) cases with subclinical hypothyroidism and 7 (44%) cases with clinical hypothyroidism (3 cases due to psychomotor developmental delay and 4 due to growth deceleration). The patients presented cli nical manifestations at 16.1 months (1.2-66.3 months) after receiving the radiopharmaceutical at acumulative dose of 142 mCi (96-391.5 mCi). No differences were found in the age at diagnosis, age at the start of treatment with 131-I-MIBG, the cumulative dose of 131-I-MIBG, and the time elapsed between the dose and the thyroid profile among the cases with or without thyroid dysfunction.

Con clusions:

56% of patients with neuroblastoma had thyroid dysfunction. Most of the cases with hypothyroidism were referred when thyroid dysfunction was clinically evident. A thyroid profile should be performed every 6 months, along with an annual endocrinological evaluation during the next 5 years in these patients.

Palabras clave : Neuroblastoma; hypothyroidism; thyroid; chemotherapy; Metaiodo benzylguanidine.

        · resumen en Español     · texto en Español | Inglés     · Español ( pdf ) | Inglés ( pdf )